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The genetics of Beckwith-Wiedemann syndrome (BWS) is complex and is thought to involve multiple genes. It is
known that three regions on chromosome 11p15 (BWSCR1, BWSCR2, and BWSCR3) may play a role in the
development of BWS. BWSCR2 is defined by two BWS breakpoints. Here we describe the cloning and sequence
analysis of 73 kb containing BWSCR2. Within this region, we detected a novel zinc-finger gene, ZNF215. We show
that two of its five alternatively spliced transcripts are disrupted by both BWSCR2 breakpoints. Parts of the 3′ end
of these splice forms are transcribed from the antisense strand of a second zinc-finger gene, ZNF214. We show
that ZNF215 is imprinted in a tissue-specific manner.
Introduction
The Beckwith-Wiedemann syndrome (BWS) (MIM
130650) is characterized by a wide variety of growth
abnormalities. Exomphalos, macroglossia, and gigan-
tism—which are the most common features—are vari-
ably present and can be found in association with mul-
tiple anomalies such as hypoglycemia, ear pits and
creases, and hemihypertrophy (Pettenati et al. 1986).
BWS patients are prone to develop several embryonic
tumors (7.5%), most commonly (40% of all tumors)
Wilms tumor (WT) (MIM 194071) (Wiedemann 1983).
Both linkage studies and the presence of chromosomal
abnormalities assigned this syndrome to chromosome
11p15.5 (Koufos et al. 1989; Ping et al. 1989), con-
taining, amongst others, the gene IGF2.
The molecular etiology of BWS is complex and in-
volves genomic imprinting (Mannens et al. 1994). Only
recently has it been possible to develop a hypothesis to
explain some of its features. It is suggested that inher-
itance of two functional copies of the primarily pater-
nally expressed IGF2 gene results in overproduction of
this fetal-growth factor and consequent changes to de-
velopment of predominantly mesodermally derived tis-
sues and organs. Evidence for this hypothesis comes
from the observation of parent-of-origin effects in BWS
where the disorder is sometimes associated with inher-
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itance of two copies of IGF2 via the paternal germline
(paternal UPD and partial trisomies) (Weksberg et al.
1996 and references therein) and the observation that
the majority of BWS patients show loss of imprinting
of this gene (Weksberg et al. 1993; Reik et al. 1995;
Brown et al. 1996; Joyce et al. 1997). More direct ev-
idence for a role for IGF2 in BWS comes from the phe-
notype of mice overexpressing or transgenic for Igf2,
which exhibit BWS-like morphological changes (Sun et
al. 1997; Eggenschwiler et al 1997).
A cluster of translocation breakpoints, contained
within an ∼300-kb interval 200–300 Kb proximal of
IGF2, defines the BWS chromosome region 1
(BWSCR1) (Hoovers et al. 1995). BWSCR1 is in the
center of a region that contains multiple imprinted genes
including IGF2, H19, CDKN1C (also known as
p57KIP2), ASCL2 (also known as HASH2), and KCNQ1
(also known as KVLQT1). All breakpoints in BWSCR1
disrupt the imprinted (maternally expressed) KCNQ1
gene (Lee et al. 1997b). The involvement of KCNQ1
in BWS and the effect of the translocations in this region
on the imprinting and expression of the other candidate
genes are not yet fully understood. In any event, in at
least two patients, disruption of BWSCR1 results in loss
of imprinting (LOI) of IGF2 (Brown et al. 1996; Smi-
linich et al. 1999).
Several observations suggest that disruption of IGF2
imprinting is not the only process involved in the eti-
ology of BWS. Recently, LIT1, an imprinted transcript
antisense to KCNQ1, was identified. LOI of this pa-
ternally expressed transcript is observed in ∼50% of the
BWS patients and seems to be independent of LOI of
IGF2. In addition, mutations in the preferentially ma-
ternally transcribed cell-cycle inhibitor CDKN1C, are
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found in a small subset of patients (Hatada et al. 1996;
Okeefe et al. 1997; Lee et al. 1997a; authors’ unpub-
lished data) and the phenotype of mice null for cdkn1c
had some similarities to BWS (Zhang et al. 1997; Yan
et al. 1997). The exact molecular events associated with
BWSCR1 rearrangements and BWS remain to be es-
tablished, but two additional regions of rearrangements
add further complexity.
BWSCR2 and BWSCR3 map, respectively, 5 Mb and
7 Mb more proximal to BWSCR1 (Redeker et al. 1994).
BWSCR2 is defined by two breakpoints and may be
associated with a distinct phenotype. Patient WH5.1 has
hemihypertrophy and ear pits and grooves and has de-
veloped a Wilms tumor. Patient CRO2 presented with
gigantism, cardiac abnormalities (dextrocardia, cardi-
omegaly, and septum defects), and hemihypertrophy
and underwent hypoglycemic crisis. Thus, both patients
have only minor BWS features—but both have hemi-
hypertrophy, a feature not seen in patients with chro-
mosomal breakpoints in BWSCR1 and BWSCR3. He-
mihypertrophy is associated with an increased risk for
childhood tumors. It is frequently present in BWS pa-
tients with Wilms tumors (40%, compared with 12.5%
in BWS patients without Wilms tumors) (Wiedemann
1983). DeBaun et al. (1998) suggest a 4.6-fold increased
relative risk in such patients. Patient WH5.1 did indeed
develop a Wilms tumor. As such, WH5.1 is the only
BWS/hemihypertrophy patient carrying a balanced
translocation that developed a childhood tumor.
The distance between the regions, the fact that they
do not disrupt the same large imprinted region, and the
phenotypic heterogeneity between the patients with
breakpoints in the different regions make it seem un-
likely that cis-acting DNA sequences are affected by
BWSCR2/3. We would suggest that an alternative hy-
pothesis could be that there is a gene(s) at BWSCR2
and BWSCR3 that interacts with some components of
the IGF2/BWSCR1 system and influences the BWS phe-
notype via this mechanism.
In this article, we describe the isolation of two zinc-
finger genes at BWSCR2: ZNF214 and ZNF215. Al-
ternative splice variants of ZNF215, partially running
antisense of ZNF214, are disrupted by the breakpoints.
ZNF215 is expressed preferentially from the maternal
allele, whereas ZNF214 is not imprinted. These data
support a role for ZNF215, and possibly for ZNF214,
in the etiology of BWS.
Material and Methods
Patient Material
Genomic DNA and high-resolution metaphase
chromosomes were isolated from Epstein-Barr
virus–transformed lymphoblastoid cell lines of pa-
tients WH5.1 (inv[11][p15.4;q22.2]) and CRO2
(t[10;11][p13;p15.4]).
Fluorescent In Situ Hybridization
Cosmids and YACs were labeled by nick-translation.
Hybridization was performed on metaphase chromo-
somes, as described previously (Hoovers et al. 1992).
Hybridization to linear DNA was performed according
to Fidlerova et al. (1994).
Construction of a Cosmid Contig
YAC A39D9 was subcloned in cosmid vector Lawrist
4. All cosmids were fingerprinted to identify potential
overlap with each other and other cosmids in a database
to construct a contig, as described elsewhere (Ivens et
al. 1994).
DNA Sequencing
Sequencing of plasmids and RACE products was per-
formed using the ABI PRISMTM Dye Terminator Cycle
Sequencing Ready Reaction Kit (PE Biosystems) and fol-
lowing manufacturer’s recommended conditions. Re-
actions were run on an ABI 377 automatic sequencer
(PE Biosystems).
Cosmids q25 and q27 were sequenced by the Sanger
Centre in Cambridge using shotgun and directed ap-
proaches. Subsequent analysis of q25 and q27 sequence
was carried out via the United Kingdom MRC Human
Genome Project Resource Centre’s Nucleotide Identify
X (NIX) front-end World Wide Web software—which
includes Grail, Fex, Hexon, MZEF, Genemark, Genefin-
der, and Blast software—either searching EMBL,
TREMBL, Swissprot, sequence-tagged-site, and ex-
pressed-sequence-tag databases or predicting gene fea-
tures de novo, as appropriate. The DNA fragment in
between q25 and q27 was isolated by PCR using pri-
mers q27F (GACCTTAAGACACACCATG) and q25R
(GCTTATGGATATCCAGCAG), cloned in pBluescript
and sequenced.
Rapid Amplification of cDNA ends (RACE)
RACE reactions were performed using Clontech’s Pla-
centa Marathon Ready cDNA kit, according to the
manufacturer’s conditions. Gene-specific primers for
ZNF215 were: 5′ RACE, Zn4 ATGAACTTCGGCA-
GAAGGC and Zn2 GTCTCAGGAATGAAAGCC
( n e s t e d ) ; a n d 3 ′ R A C E , Z n 7 C C T T C A -
ACCGGAGCTCCTC and ME1 TGCATACTCGAGA-
TAAGTCCTG (nested). Gene-specific primers for
ZNF214 were: 5′ RACE, 835R1 ATTTGAAGATTT-
GAGCGCTGGGTA and 835R2 CCCTTACCACACT-
CATCACAC (nested); 3′ RACE, 833R1 GGGATT-
CAGTCAGCGTTCACAT and 833R2 CAATGTGCT-
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AAGTGTGGTAAAGG (nested). PCR products were
cloned in pUC18 using the Sureclone ligation kit (Pro-
mega).
Amplification of the ZNF215 Alternative Transcripts
cDNA was synthesized from 3 mg RNA using MMulV
reverse transcriptase (Promega) and poly dT primer in
20 ml. 5 ml cDNA was used for PCR, using primers V3R
(GACGGTAACTTTCATCAGAGC) and 215F1 (CAT-
GACTCTGAGGCATCTCG) to amplify V3 and V1R
and 215F1 to amplify V1,V4, and V5.
Green Fluorescent Protein Fusions
Full-length ZNF215V1 cDNA was generated by sub-
cloning the KpnI-HindIII fragment from the 5′ RACE
product and the HindIII-EcoRV fragment containing
part of exon 7 from q25, into the KpnI and EcoRV
restriction site in pcDNA3. In order to clone the coding
sequence in frame with GFP in pEGFP, ZNF215V1 was
amplified using primers with KpnI and BamHI linkers
GAGGTACCGCTATCTCAAAACCTCGAA (F) and
CAGGATCCATGAGATTTTATCCAGCA (R) and was
cloned in pEGFPC1.
Full-length ZNF214 cDNA was generated by sub-
cloning the HaeIII-KpnI fragment from the 5′ RACE
product and the KpnI-AvrI fragment containing the zinc
fingers isolated from q27 into the EcoRV-XbaI sites in
pcDNA3. ZNF214 was amplified using primers with
BamHI and XhoI linkers CAGGATCCGCAGTAA-
CATTTGAAGATG (F) and GACTCGAGGTAAACT-
TTGATTAAAGCTG (R) and was cloned in pEGFPC1.
Hep3b cells and cos-7 cells were plated at 10% density
and were grown for 8 h on microscopy slides in six-
well plates. 2 mg plasmid DNA (ZNF214-pEGFPC1,
ZNF215V1-pEGFPC1, and pEGFPC1 [control]) was
transfected overnight in 1 ml serum-free medium and 10
ml lipofectin (GIBCO BRL). After transfection, the me-
dium was refreshed and cells were grown for another 8
h. Then cells were fixed in 4% paraformaldehyde, were
dehydrated in alcohol series, and were mounted in Vec-
tashield (Vector Laboratories).
Determination of Genomic Imprinting
ZNF215.—Genomic DNA was amplified using prim-
ers 5PZ (GAACTGTTGGTGCTGGAAC) and 5P1
(TCTGGCACTTGATACTCTCT) RT-PCR was per-
formed on RNA isolated from tissues of heterozygous
individuals. cDNA was synthesized from 1 mg RNA us-
ing MMulV reverse transcriptase (promega) and the in-
ternal primer V1R (GTCTCAGGAATGAAAGCC) (V1)
or V3R (GACGGTAACTTTCATCAGAGC) (V3) in 20
ml. 5 ml cDNA was used for PCR using primers V1R/
5PZ or V3R/5PZ to amplify ZNF215V1 and
ZNF215V3, respectively. A nested PCR was performed
on both using primers 5PZ and 5PR (TGCAGGGCA-
TATCTTCATCT) to get the same fragments for both
variants.
The PCR products were analyzed on a 12.5% non-
denaturing AA gel and run at 57C 600V, 25 mA for 3
hours on a genephor system (Amersham Pharmacia
Biotech).
ZNF214.—Genomic DNA was amplified using prim-
ers 214F1 (GCTTTTATCTCACCATGGG) and 214R1
(TCTAAGGACTGCCAAGGC) RT-PCR was performed
on RNA isolated from tissues of heterozygous individ-
uals. cDNA was synthesized from 1mg RNA using
MMulV reverse transcriptase (promega) and the internal
primer 214R2 (CCATTGAATCTCTCAGTAGG) in 20
ml. 5 ml cDNA was used for PCR using primers 214F2
(TGGAAATTCCTGGATTCTTC) and 214R2. (semi-
)Nested PCR was performed using primers 214F2 and
214R1. Sequencing was performed using Cy5-labeled
primers on an ALFexpress automated sequencer (Amer-
sham Pharmacia Biotech).
Mutation Analysis
DNA was isolated from peripheral blood lymphocytes
of 32 BWS patients and 11 hemihypertrophy patients
(all non-UPD cases). The coding regions of ZNF214 and
ZNF215 were amplified by PCR (primers available on
request). PCR products analyzed by SSCP on 12.5%
nondenaturing polyacrylamide gels (Amersham Phar-
macia Biotech) ran at 57C and 157C, as described in
GeneGel Excel protocols (Amersham Pharmacia Bio-
tech). DNA was stained using the Silver staining kit
(Amersham Pharmacia Biotech). PCR products present-
ing abberant conformers were reamplified from genomic
DNA and were sequenced in both directions by the fluo-
rescent dideoxy chain–termination method on an ABI
377 sequencer (PE Biosystems).
Results
Construction of a Cosmid Contig over the Breakpoints
It has previously been shown that BWSCR2 is located
between D11S776 and HPX (Redeker et al. 1995). By
screening a YAC library with cosmid e2378 (D11S776)
we isolated YAC A39D9 that, by FISH analysis, over-
lapped the two breakpoints (data not presented). Cos-
mids subcloned from the YAC A39D9 were finger-
printed to identify potential overlap with each other and
with other cosmids in the database (see Methods). We
constructed a contig of 150 kb (fig. 1a) and the integrity
of this contig was checked by hybridization on extended
DNA (fig. 1c, d). Rearrangements in patients CRO2 and
WH5.1 define BWSCR2 and FISH analysis shows that
the cosmid q27 spans the CRO2 breakpoint (fig. 1b).
Southern blots of WH5.1 DNA probed with fragments
Figure 1 Localization of the breakpoints. a, Schematic map of chromosome 11p15. The three different breakpoint regions are indicated.
The translocation breakpoint of the rhabdoid tumor Tm87-16 also maps within BWSCR1. The cosmid contig in BWSCR2 is shown, as well
as the localization of the breakpoints. b, Cosmid q27 hybridized to chromosomes of patient CRO2. Signals are visible on the normal 11, the
derivative 11 and the derivative 10, indicating that this cosmid spans the breakpoint. c, FISH on linearized DNA, performed with cosmids q25
(red), q27 (green) and u280 (green) d, FISH on linearized DNA performed with cosmids q25 (green), q27 (red), and u280 (green). e, EcoRI
digests of DNA derived from WH5.1, his father (WH5.2), his mother (WH5.3), and reference patients, hybridized with a fragment derived
from q25. Two aberrant bands are detected in WH5.1 and WH5.3, indicating that this 7-kb EcoRI fragment contains the breakpoint.
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Figure 2 Schematic representation of the BWSCR2 region. The breakpoint WH5.1 could be localized to a 1138-bp TaqI fragment. The
position of CRO2 is not precisely mapped and is thought to be located in the last 15 kb of q27. Cosmids q25 and q27 were completely
sequenced, allowing precise mapping of the exons of ZNF214 and ZNF215 in this region. Exons 3–7, covering the coding part of ZNF215,
are present in cosmid q25; alternative exons 8 and 9 are present in cosmid q27. Exons 2 and 3 of ZNF214 were found at the centromeric end
of q27. Exon 1 maps outside q27, and its localization is not yet known. The coding regions of the genes are stained black, and the 3′ UTRs
and 5′ UTRs are depicted in gray.
derived from q25 showed that the breakpoint mapped
to a ∼7-kb EcoRI fragment (fig. 1e). Additional exper-
iments refined this localization to a 1138-bp TaqI frag-
ment (data not shown).
Zinc-Finger Genes Are Associated with BWSCR2
In a previous study (Hoovers et al. 1992), we dem-
onstrated that cosmid e2378, that contains D11S776,
contains zinc-finger motifs. The presence of this cosmid
in the contig that overlaps the breakpoints led us to
search for other zinc-finger motifs in this region, using
a degenerate oligo coding for the conserved C2H2-zinc-
finger linker sequence HTGEKPY. Positive signals were
observed in e2378 and in overlapping cosmids, and in
q25, q24, and cSRL7e1. The positive fragments were
subcloned and sequenced, and zinc-finger motifs were
detected. Subsequently, we identified these motifs as be-
ing derived from two zinc-finger genes, ZNF214 and
ZNF215, respectively encoded in q27 and q25. These
observations suggested there might be zinc-finger–
coding genes disrupted by the breakpoints in patients
CRO2 and WH5.1. We therefore sequenced cosmids
q25 and q27 to determine whether this was the case.
Sequence Analysis
Cosmids q27 and q25 were completely sequenced by
the Sanger Centre. The 686-bp gap between q25 and
q27 subsequently was isolated by use of PCR (see Ma-
terial and Methods) and also were sequenced, which led
to a 73-kb continuous sequence. Separately, the zinc-
finger sequences generated from q27 and q25 were used
to screen cDNA libraries and to carry out RACE to
isolate cDNAs for both genes. Extensive computer anal-
ysis (see Methods) of the cosmids detected only the two
zinc-finger genes—ZNF214 and ZNF215—and, among
others, an EST (AA639668) mapping to the region.
Analysis of the complete sequences of the two cosmids
and comparison to the cDNA sequences enabled us to
show that ZNF214 is located at the proximal end of
q27 and transcription is towards the telomere; ZNF215
is located towards the proximal end of q25 and is tran-
scribed towards the centromere: ZNF214 and ZNF215
are therefore transcribed convergently. The exon 1 of
ZNF214 is not contained in q27: exon 2 is at 371–517
and exon 3 at 1671–3920. Three ESTs were found that
run until 4695 or 5046, and probably represent tran-
scripts that use alternative polyadenylation sites. Simi-
larly, exons 1 and 2 of ZNF215 are encoded outside of
q25; exon 3 is at 32721–32143, exon 4 at 23241–
23157, exon 5 at 21729–21597, exon 6 at 21266–
21171, and exon 7 at 9123–6767.
EST AA639668 contains part of exon 7 of ZNF215
(9123–9031), and two novel exons: 8 (at 14997–14903
in q27) and 9 (at 2532–2205 in q27). The latter runs
antisense of ZNF214 (fig. 2). This suggests that ZNF215
is alternatively spliced, and this was tested by RT-PCR
experiments making use of (1) primers derived from
exon 3 and exon 9 and (2) mRNA from fibroblasts and
the hepatoma cell-line Hep3B (fig. 3). Sequence analysis
of resulting products showed that an mRNA was pro-
duced that contained exons 3, 4, 5, 6, 7, and 9, but not
exon 8 (V3 in fig. 2). Additional RT-PCR experiments
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Figure 3 Alternative transcripts of ZNF215. a, RT-PCR performed on fibroblasts and Hep3b RNA, using primers derived from exon 9
and exon 3. An 831-bp fragment is produced, representing ZNF215V3. b, Tissue-specific expression of the ZNF215V4 and ZNF215V5 splice
variants. Kidney, liver, and placenta express predominantly the ZNF215V1 RNA. The smaller variants, ZNF215V4 and ZNF215V5 are expressed
in brain tissue. This was reproducible in three more brain samples and two more kidney samples (data not shown).
Figure 4 a, Schematic representation of the ZNF214 gene. The
KRAB domain and the zinc-finger region are indicated. b, Schematic
representation of the ZNF215V1 gene. The SCAN box, KRAB domain
and the zinc-finger region are indicated
also revealed the presence of two additional splice forms,
V4 and V5, which lack exon 5 and exons 5 and 6,
respectively (fig. 2). These splice variants show a tissue-
specific expression pattern (fig. 3). In general, both
ZNF214 and ZNF215V1 are widely expressed at very
low levels by northern analyses. Expression is highest in
the testis (data not shown). ZNF215V2–ZNF215V5 are
not detectable on northern blots, but they can be am-
plified by RT-PCR from several fetal and adult tissues.
ZNF214 and ZNF215 Proteins
ZNF214 (fig. 4a) contains 12 zinc fingers—of which
fingers 1, 2, and 4 lack a cysteine, whereas fingers 2 and
4, respectively, lack a leucine and a phenylalanine residue
in the consensus finger sequence, C X2 C X3 F X5 L X2
H X3 H. At the N-terminal ZNF214 contains a KRABA
domain. ZNF215 (fig. 4b) contains four zinc fingers,
which are present in two pairs of two, with a small
spacer in between. ZNF215 contains a KRABA domain;
similarities to a KRABB domain; and, at the amino-
terminal, a SCAN box. A nuclear localization signal,
KKKR, was also present. In the variants represented by
ZNF215V3 and EST AA639668 (V2), the alternative
splicing in exon 7 leads to truncated proteins consisting
of only the SCAN box and KRAB domain and excluding
the zinc fingers. In the ZNF215V3 variant, lacking exon
8, the open reading frame continues coding for 98 ad-
ditional amino acids. In variants ZNF215V4 and
ZNF215V5, the alternative splicing causes a frameshift,
allowing only the synthesis of the SCAN box.
Zinc-finger proteins that are involved in transcription
regulation exert their function in the nucleus. If ZNF214
and ZNF215 were involved in transcriptional regula-
tion, in the most general sense, we would expect them
to be located in the nucleus. We tested this by fusing the
V1 cDNA of ZNF215 and the full-length cDNA of
ZNF214 to the green fluorescent protein (GFP) in p-
EGFPC1. Transfection of these constructs to cos-7 or
Hep3b cells showed that, after 24 h, both ZNF214 and
ZNF215 are present in the nucleus. Transfection of the
control construct, the empty pEGFPc1 vector, led to
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Figure 5 Subcellular localization of ZNF214 and ZNF215 Hep3b cells transfected with the empty pEGFPC1 vector (a), the GFP-ZNF214
(b), and GFP-ZNF215 (c) fusion proteins. Staining of GFP alone is seen throughout the whole cell. ZNF214 and ZNF215 are transported to
the nucleus and display a speckled pattern of staining.
Table 1
Summary of Imprinting of ZNF215V1 and
ZNF215V3
Fetus and Tissue ZNF215V1 ZNF215V3
1f:
Heart M 1/≈ P M
Lung M 1 P M 1 P
Kidney M 1 P ND
Testis M 1 P ND
Brain M ≈ P M 1/≈ P
2f:
Heart ND M
Liver M 1 P M 1 P
Kidney M 1 P M 1 P
Brain M ≈ P M
NOTE.— , equal expression maternalM ≈ P
and paternal alleles; , preferential ex-M 1 P
pression of the maternal allele; M, expression
almost exclusively from the maternal allele; M
1/≈ P, roughly equal expression slightly favoring
the maternal allele; ND, not done.
staining throughout the whole cell (fig. 5). We note a
speckled pattern of staining in the nucleus, excluding the
nucleoli, which might indicate that the proteins are pre-
sent in specific nuclear bodies or domains.
Genomic Imprinting
The molecular etiology of BWS clearly involves im-
printing and loss of imprinting control, but there is no
a priori reason to suggest that genes at BWSCR2 need
to be imprinted, although both translocations in this
region are maternally inherited. Nevertheless, we tested
ZNF215 and ZNF214 to determine whether this was
the case. We screened DNA of 10 normal fetuses and
their mothers for polymorphic sites in both genes.
An ArG change at position 355 was identified in
ZNF215. Two fetuses were heterozygous for this poly-
morphism while their mothers were homozygous. RNA
isolated from different tissues of these two fetuses was
used to determine allelic expression patterns of variants
ZNF215V1 and ZNF215V3. SSCP analysis of appro-
priate RT-PCR products of ZNF215V1 and ZNF215V3
(fig. 6a, b, c, d) shows that the maternal allele of
ZNF215V1 is preferentially expressed in liver, lung, kid-
ney, and testis but also that, in the brain and heart, these
alleles are nearly equally expressed. Interestingly,
ZNF215V3 also is partially imprinted in lung, liver, and
kidney but is completely imprinted in heart. In brain
tissue, however, complete imprinting is seen in fetus 2,
whereas, in fetus 1, both alleles are expressed—
indicating either that, at least in this tissue, individual
variation exists or that imprinting may vary in different
stages of development (developmental stages of the fe-
tuses used are not known). A summary of the results is
shown in table 1.
In ZNF214, we found a polymorphism at position
383 (TrG and TrA). Sequencing analysis of appropri-
ate RT-PCR products of ZNF214 showed that both al-
leles are expressed at roughly equal intensities in heart,
lung, brain, and liver, indicating that ZNF214 is not
imprinted.
Figure 6 Genomic imprinting of ZNF215. a, Schematic overview of the primers used for amplification of ZNF214 and ZNF215V1 and
ZNF215V3. RT indicates primers used for reverse transcription. b, SSCP of ZNF215 genomic and cDNA. Both fetuses (1f and 2f) are
heterozygous, whereas their mothers (1m and 2m) are homozygous. SSCP analysis of ZNF215V1 cDNA derived from different tissues of 1f
and 2f homozygous control samples.shows that both alleles are expressed, although the maternal allele is more abundantly expressed in all
tissues except brain and heart. SSCP analysis of ZNF215V3 cDNA shows that expression is predominantly from the maternal allele in lung,
liver, kidney, and brain of 1f. Expression is exclusively from the maternal allele in heart and brain of 2f. c, Sequence analysis of ZNF214 on
genomic heterozygous DNA and RT-PCR products of ZNF214 derived from different tissues of 1f and 2f shows no indication for imprinting.
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Figure 7 Variations in ZNF214 and ZNF215. a, Sequence analysis of ZNF214 in patient HH5, who has the R252C variant, and a control
individual. b, Alignment of the twelve zinc fingers of ZNF214. The amino acids of the conserved zinc-finger consensus sequence are indicated.
The variable sites are indicated with red circles. The R252C variant restores the first imperfect zinc-finger, and the R426H is in the seventh
zinc-finger. c, Sequence analysis of ZNF215 in patient B34 and a control individual. d, SSCP pattern of fragment 8 of ZNF215 from patient
B34, her father (B34F) and her mother (B34M). The variant is inherited from the mother.
Mutational Analysis
Only two chromosomal rearrangements define
BWSCR2. If either or both of ZNF214 and ZNF215 do
indeed play a role in BWS, then we might expect mu-
tations to be found in these genes in at least a subset of
cytologically unaltered BWS patients. To search for
these, we set up an SSCP strategy to screen for mutations
in both genes in 32 patients with BWS and 11 patients
with isolated hemihypertrophy (all non-UPD cases). In
ZNF214, we found a 754CrT change in 6 of 44 patient
samples (2 from patients with BWS, 2 from patients with
BWS with hemihypertrophy, and 2 from patients with
isolated hemihypertrophy), compared to 2 of 205 con-
trol individuals (significant at ). This change re-P ! .01
sults in an arginine-to-cysteine conversion in the first
finger and restores this normally imperfect finger (fig.
7b). In addition a 1277GrA change, leading to a R426H
substitution in the seventh zinc-finger, was found in a
single patient (fig. 7b). This alteration is inherited from
the presumably unaffected father.
In ZNF215, a 988GrT transition was found in 1
patient with BWS (fig. 7c, d). This variant was also found
in the mother of the patient and was not present in 48
control individuals. The transition changes a glycine to
a tryptophan in a potential phosphorylation site
(RKGS).
Discussion
In this study, we set out to test the hypothesis that there
could be a gene(s) located at the BWSCR2 region that
could contribute to the BWS phenotype. The two chro-
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mosomal rearrangements that define BWSCR2 both dis-
rupt the zinc-finger gene ZNF215, thus meeting the first
formal requirement for any gene’s involvement in the
etiology of BWS—that it must be disrupted by the
rearrangements.
The breakpoints in BWSCR2 disrupt alternative-
spl iced ZNF215 transcripts (ZNF215V2 and
ZNF215V3). These transcripts encode a truncated pro-
tein lacking the zinc fingers but retaining the KRAB and
SCAN box functional domains. KRAB domains are
found in about one-third of all C2H2-class zinc fingers
and transfection experiments have shown that it is able
to repress transcription (Margolin et al. 1994; Witzgall
et al. 1994). The function of a SCAN box is still un-
known but its a-helical structure suggests that it may
serve as a dimerization domain (Williams et al. 1995).
It is an attractive but speculative hypothesis that, on the
basis of their respective protein motifs, ZNF215V1 is
a zinc-finger transcription factor and that ZNF215V2
and ZNF215V3 are regulatory proteins. The finding
that both ZNF214 and ZNF215V1 proteins are trans-
ported to the nucleus, as determined by transfection
studies using GFP fusion proteins, is compatible with
such a role. Alternative-spliced transcripts encoding
truncated proteins are also found in some other tran-
scription factors—for example, some members of the
HOX gene family, whose alternative transcripts encode
proteins lacking the homeobox domain (La Rosa et al.
1988; Shen et al. 1991; Hong et al. 1995; Fujimoto et
al. 1998). The ZNF215V2 and ZNF215V3 alternative-
spliced transcripts are partially antisense of ZNF214,
and it is possible that transcription of ZNF215V2 and
ZNF215V3 may modulate levels of ZNF214 transcrip-
tion or translation.
Although we found some alterations in ZNF214 and
ZNF215 in patients, we do not have evidence for func-
tional mutations in these genes. The incidence of the
252C allele in ZNF214 is significantly higher in BWS
than in the unaffected population, but its involvement
in these diseases cannot yet be considered proven. A
more direct test of function will be required to prove a
causal relationship. The significance of the single
R426H variant in ZNF214 and the G330W variant in
ZNF215 is unclear.
The finding that ZNF215V1 and ZNF215V3 are im-
printed may be significant. Both BWSCR2 rearrange-
ments are maternally derived suggesting these two pa-
tients will harbor an active but rearranged ZNF215
gene and a paternally derived, unrearranged, but pre-
dominantly inactive normal gene.
BWSCR2 appears to be associated with hemihyper-
trophy, unlike rearrangements of BWSCR1 or
BWSCR3. The mouse models of BWS suggest involve-
ment of CDKN1C and IGF2 but fail to account for the
presence of hemihypertrophy. The cdkn1c null mouse
develops some BWS features such as omphalocoele and
other abdominal-wall defects, but no overgrowth
(Zhang et al. 1997; Yan et al. 1997). The Igf2 transgenic
mouse shows gigantism and organomegaly (Sun et al.
1997). Together, these mice account for a large pro-
portion of BWS features, but not hemihypertrophy. It
has been suggested that mosaic UPD causes the local
hypertrophy, but chimaeric transgenic Igf2 mice do not
show this and the translocations involving BWSCR2 are
constitutional. It is possible that hypertrophy is the
product of a local stochastic event (possibly IGF2 ac-
tivation) that can be largely asymmetric (hemihypertro-
phy) or largely symmetric (organomegaly). Evidence for
this hypothesis does not yet exist and will require a
proper understanding of the functions of the ZNF214
and ZNF215 proteins.
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